Basilea Pharmaceutica

U.S. trade commission ends waiting period for drug companies' collaboration

Published in Medicine and Law Weekly, January 14th, 2005

The U.S. Federal Trade Commission recently announced that it granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to a notification and report filed by Johnson & Johnson and Basilea Pharmaceutica AG.

Basilea and Ortho-McNeil Pharmaceutical, Inc, a Johnson & Johnson company, are in negotiations related to a potential license agreement on Basilea's phase 3, broad-spectrum cephalosporin antibiotic, ceftobiprole (BAL5788), that has activity against methicillin-resistant Staphylococcus aureus (MRSA).

Basilea has been in discussions with a number of potential partners related to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2005-01-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry